Executive Orders Targeting Prescription Drug Prices: Agency Objectives, Healthcare Industry Impact, Compliance Issues
A live 90-minute CLE video webinar with interactive Q&A
This CLE webinar will examine two recently released executive orders (EOs) issued by the new administration related to prescription drug pricing and discuss how these may affect the healthcare industry and who may be most impacted. The panel will discuss the agency objectives outlined in each EO, address agency action to date, and provide best practices for helping healthcare clients navigate this rapidly changing regulatory environment.
Outline
- Introduction
- Understanding the executive orders
- Lowering Drug Prices by Once Again Putting Americans First
- Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients
- Agency objectives
- Agency action to date
- Potential healthcare industry impact
- Remaining questions and compliance challenges
- Best practices for compliance
Benefits
The panel will review these and other key issues:
- How are the administration's policies related to prescription drug pricing reflected in each EO?
- What agencies are impacted by the EOs? What agency action will be required? What agency action has been taken to date?
- Who in the healthcare industry may be most impacted by the EOs' directives? In what ways?
- What questions are left unanswered by the EOs? Creating what compliance challenges?
Faculty
Theresa C. Carnegie
Member
Mintz
Ms. Carnegie has extensive experience advising clients on all aspects of the pharmaceutical supply chain. Her practice... | Read More
Ms. Carnegie has extensive experience advising clients on all aspects of the pharmaceutical supply chain. Her practice involves advising industry stakeholders on a range of business, legal, transactional, and compliance matters. Ms. Carnegie combines her multilayered industry knowledge with a deep understanding of applicable federal and state legal frameworks, in particular federal and state fraud and abuse laws. She provides clients with strategic counseling and creative business modeling that considers legal restrictions and regulatory risk in light of innovation and business goals. Ms. Carnegie is a frequent author and speaker on regulatory and policy issues affecting pharmacy benefits and the pharmaceutical supply chain.
CloseEarly Discount (through 08/15/25)